Imviva Reports High Response Rates for T‑Cell Leukemias at EHA 2026 — Up to 86%

Imviva Biotech announced results from two clinical datasets on relapsed or refractory T‑cell acute lymphoblastic leukemia (T‑ALL) and lymphoblastic lymphoma at the European Hematology Association (EHA) 2026 Congress in Stockholm.

Key Trial Results

The global TENACITY‑01 study in adults produced an overall response rate (ORR) of 85.7%, with a complete remission (CR) rate of 71.4%, Imviva reported. These data reflect responses among adults with relapsed or refractory T‑ALL and lymphoblastic lymphoma.

Separately, a Phase 1/2 study of CTD402 — an off‑the‑shelf, allogeneic CAR T‑cell therapy — showed an 80% complete remission rate in pediatric patients with the same diagnoses.

“The combination of strong efficacy — with 80% of pediatric patients achieving complete remission — and a favorable safety profile, alongside CTD402’s immediate availability as an off‑the‑shelf therapy, demonstrates the potential to address a critical unmet need in this patient population,” said Jan Davidson‑Moncada, MD, PhD, Chief Medical Officer of Imviva Biotech.

Safety and Clinical Context

Imviva highlighted a favorable safety profile for CTD402 in the pediatric cohort and emphasized the potential advantages of an allogeneic, immediately available CAR T product versus autologous approaches that require individualized manufacturing. Full safety data and longer follow‑up from both studies will be important to confirm durability of responses.

Imviva presented these findings as part of the EHA 2026 scientific program (June 11–14, Stockholm). Detailed data and poster/oral presentation identifiers are expected to be available in the congress abstracts and company materials.

Contact: Exec Edge — [email protected]

Source: Imviva Biotech press release and EHA 2026 program